Publications by authors named "Alexandre Lejeune"
Article Synopsis
- The ALLEGRO studies show that ritlecitinib is effective and well-tolerated for treating alopecia areata in patients aged 12 and older for up to 24 months.
- Results indicate significant improvement in hair regrowth, with a marked increase in patients achieving favorable Severity of Alopecia Tool (SALT) scores at both 12 and 24 months.
- The safety profile of ritlecitinib remains consistent with previous studies, confirming its long-term tolerability for users.
Article Synopsis
- * A safety analysis of four studies showed that adverse events (AEs) occurred in about 70-75% of patients on ritlecitinib compared to 69.5% in the placebo group, with some patients experiencing serious AEs.
- * Overall, ritlecitinib is deemed well tolerated and presents an acceptable safety profile over a 24-month period for adolescents and adults with AA.
Article Synopsis
- Alopecia areata (AA) is an autoimmune condition causing hair loss that can range from small patches to total loss of hair on the scalp and body, linked to immune responses targeting hair follicles.
- Current treatment options are limited, with only two FDA-approved systemic drugs, baricitinib and ritlecitinib, specifically for severe AA, while other off-label treatments exist but often lack effectiveness and safety.
- The review discusses the role of T cells in AA's development and explores new therapeutic approaches being researched that target various T-cell signaling pathways, aiming for more effective treatments beyond just JAK inhibitors.
Article Synopsis
- Ritlecitinib is a small molecule that specifically inhibits JAK3 and TEC family kinases, currently being tested in clinical trials.
- A phase 1 study involving healthy participants tested two single doses (50 mg and 200 mg), measuring the drug’s effects on target occupancy and functional signaling through blood samples collected over 48 hours.
- The results showed high target occupancy for JAK3 and TEC kinases, with ritlecitinib effectively reducing specific signaling markers in a dose-dependent manner, indicating its potential for dual-pathway inhibition, but further research is required to clarify its clinical benefits.
Background: Despite an increasing preference of consumers for beef produced from more extensive pasture-based production systems and potential human health benefits from the consumption of such beef, data regarding the health status of animals raised on pasture are limited. The objective of this study was to characterise specific aspects of the bovine peripheral and the gastrointestinal muscosal immune systems of cattle raised on an outdoor pasture system in comparison to animals raised on a conventional intensive indoor concentrate-based system.
Results: A number of in vitro functional tests of immune cells suggested subtle differences between the animals on the outdoor versus indoor production systems.